Dermatology space to benefit most from five potential blockbusters
According to GBI Research, Dupixent is expected to face very little competition and as a result will generate the second highest…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Management
Let’s move this story forward
Bharathi Ghanashyam, Founder &Editor, Journalists against TB, talks about the story of (multi-drug-resistant tuberculosis) MDR…
Global dermatology market set to benefit extensively from pipeline biologics
According to GBI Research, the use of biologics in dermatology has gained prominence over the years, primarily in psoriatic…
Long-acting therapies could transform HIV treatment by boosting compliance
Adherence challenges or incarcerated patients might find this kind of antiretroviral regimen desirable
NASH market will increase more than 40 fold by 2026
Rising rate of obesity and diabetes globally and launches of multiple late-stage pipeline products will transform the market
Asia-Pacific asthma market will hit $6 billion by 2023
According to GBI Research, the strong growth will be driven by an expanding aging population, increase in air pollution, a…
First-in-class innovation a key strategy for pharma companies in a harsh market environment: GBI…
The report also mentions that a product entering into clinical development has a 72 per cent likelihood of failing to reach the…
Haematological cancers pharma pipeline one of the strongest within oncology: GBI Research
The haematological cancers pipeline, which covers leukaemia, lymphoma and myeloma, is the largest within the oncology therapy area…
Global immunology market to surpass $75 bn by 2022 despite patent expirations
According to GBI research, the large immunology pipeline consists of 2,054 products in active development, almost 100 of which are…
Growth hormone deficiency market to grow steadily, surpassing $2 bn by 2026
According to a report by GlobalData, major drivers of this growth include the launch of long-acting growth hormones, improved…
The right balance?
The release of the Schedule Y amendment on January 20, 2005 and the CDSCO notice dated October 5, 2016 about the ‘SUGAM’ portal…
What more for clinical research in India?
Dr Chirag Trivedi, President, Indian Society for Clinical Research (ISCR),emphasises on the importance of clinical trials in drug…
Quality with a supersized Q
Naz Haji, SVP and Managing Director, QuintilesIMS India, elaborates on the need to improve awareness amongst the Indian public…
Building on strengths
Boehringer Ingelheim is undergoing a comprehensive transformation to derive more growth and value through strategic realignment of…
Pipeline drug offers promise in treatment of platinum-resistant ovarian cancer: GlobalData
ImmunoGen announced that the first patient was dosed in its pivotal Phase III study that investigates mirvetuximab soravtansine as…
Bladder cancer market size to more than triple to over $1.1 billion by 2025
The growth will be driven by the increased incorporation of immunotherapies into treatment algorithms, the launch of new…
Strict or stringent national regulatory authority for procurement of anti-tuberculosis medicines?
John F Loeber, Chief Procurement Officer, UN Stabilisation Mission in Haiti (MINUSTAH) Port-au-Prince, Haiti, in this article…
Fatty liver disease prevalence leads pharma companies look to first in-class drugs
According to GBI Research, fatty liver disease has increased rapidly in the past several decades and is now estimated at 20-45 per…
Global cancer supportive care therapeutics market to see negligible growth to $12.4 billion by 2022
According to GBI Research, negligible growth can be attributed to the patent expiries of some of the therapy area’s most…
Partnerships with healthcare organisations, government aid disaster management
Shripad Desai, MD and Country Director , Americares India Foundation, Mumbai, explains how synergy between NGOs, pharmaceutical…